Considering the long life of the CVRs (end date 12/2029), the relatively low cost of the first milestone ($10 million), and that there was no reason to buy OCRX other than to try bring the compound to market, I don't see MNK dragging their heels. The sooner they can get into a definitive trial the sooner they can get a positive return on their investment.
Now for the sales milestone, sure, if sales get close to to required half billion then MNK would likely factor that milestone payment into their sales efforts.
I'm sure the OCRX board would have preferred more money up front also, but after the troubles of the Phase 2 trial and all the uncertainty whether this product will ever be approved, it seems perfectly reasonable to have a CVR. Fortunately it just requires trial enrollments and not approval so faster to payments
